Giorgio Palú, President of the Italian Medicines Agency (AIFA) helps us understand how the agency works, explains the criteria they use to evaluate innovative medicines and tells us about AIFA’s independent research program.
AIFA has always favoured innovation and, in this context, has defined specific criteria with the aim of guaranteeing quick access to medicines that have a clear therapeutic added value and of incentivising the development of drugs that offer substantial therapeutic benefits for patients.
